Table 3.

Correlation between clinicopathological features and each intrinsic subtype in 55 patients with recurrence after surgery

Parameters	Intrinsic subtype				p-value
	Luminal (n = 23)	Luminal-HER2 (n = 3)	HER2-enriched (n = 9)	TNBC (n = 20)
Age at operation
≤ 56	13 (56.5%)	2 (66.7%)	5 (55.6%)	11 (55.0%)
> 56	10 (43.5%)	1 (33.3%)	4 (44.4%)	9 (45.0%)	0.985
Menopause
Pre-	10 (43.5%)	2 (66.7%)	4 (44.4%)	8 (40.0%)
Post-	13 (56.5%)	1 (33.3%)	5 (55.6%)	12 (60.0%)	0.860
Tumor size (cm)
≤ 2	2 (8.7%)	0 (0.0%)	1 (11.1%)	2 (10.0%)
> 2	21 (91.3%)	3 (100.0%)	8 (88.9%)	18 (90.0%)	0.888
Lymph node status
Negative	2 (8.7%)	1 (33.3%)	2 (22.2%)	5 (25.0%)
Positive	21 (91.3%)	2 (66.7%)	7 (77.8%)	15 (75.0%)	0.437
Nuclear grade
1, 2	18 (78.3%)	3 (100.0%)	8 (88.9%)	16 (80.0%)
3	5 (21.7%)	0 (0.0%)	1 (11.1%)	4 (20.0%)	0.620
Ki67 (%)
≤ 14	11 (47.8%)	3 (100.0%)	4 (44.4%)	8 (40.0%)
> 14	12 (52.2%)	0 (0.0%)	5 (55.6%)	12 (60.0%)	0.175
Pathological response
Non-pCR	17 (73.9%)	3 (100.0%)	5 (55.6%)	16 (80.0%)
pCR	6 (26.1%)	0 (0.0%)	4 (44.4%)	4 (20.0%)	0.306
Metastatic site
Local/bone	16 (69.6%)	2 (66.7%)	5 (55.6%)	12 (60.0%)
Distant	7 (30.4%)	1 (33.3%)	4 (44.4%)	8 (40.0%)	0.866
Relapse-free survival (years)
< 2	13 (56.5%)	1 (33.3%)	5 (55.6%)	16 (80.0%)
≥ 2	10 (43.5%)	2 (66.7%)	4 (44.4%)	4 (20.0%)	0.220

HER2 human epidermal growth factor receptor 2, TNBC triple-negative breast cancer, pCR pathological complete response